These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25468895)

  • 1. Quantitative imaging of enzymatic vitreolysis-induced fiber remodeling.
    Filas BA; Shah NS; Zhang Q; Shui YB; Lake SP; Beebe DC
    Invest Ophthalmol Vis Sci; 2014 Dec; 55(12):8626-37. PubMed ID: 25468895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy.
    Gandorfer A; Putz E; Welge-Lüssen U; Grüterich M; Ulbig M; Kampik A
    Br J Ophthalmol; 2001 Jan; 85(1):6-10. PubMed ID: 11133703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biology of pharmacologic vitreolysis.
    Sebag J
    Trans Am Ophthalmol Soc; 2005; 103():473-94. PubMed ID: 17057814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of the structure of enzymatically-degraded bovine vitreous using synthetic proteoglycan mimics.
    Zhang Q; Filas BA; Roth R; Heuser J; Ma N; Sharma S; Panitch A; Beebe DC; Shui YB
    Invest Ophthalmol Vis Sci; 2014 Oct; 55(12):8153-62. PubMed ID: 25342623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of plasmin on the vitreolysis in rabbit eyes.
    Kim NJ; Yu HG; Yu YS; Chung H
    Korean J Ophthalmol; 2004 Jun; 18(1):35-40. PubMed ID: 15255235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients.
    Sebag J; Ansari RR; Suh KI
    Graefes Arch Clin Exp Ophthalmol; 2007 Apr; 245(4):576-80. PubMed ID: 16941141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the Spatiotemporal Material Anisotropy of the Vitreous Body in Tension and Compression.
    Shah NS; Beebe DC; Lake SP; Filas BA
    Ann Biomed Eng; 2016 Oct; 44(10):3084-3095. PubMed ID: 26983839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocriplasmin for pharmacologic vitreolysis.
    Kuppermann BD
    Retina; 2012 Sep; 32 Suppl 2():S225-8; discussion S228-31. PubMed ID: 22929326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Assessment of Pharmacologic Vitreolysis in Rabbits With the Digital Fluoroscopy System.
    Bae JH; Park HS; Kim JM; Lee BR; Lee SC; Tandogan T; Auffarth GU; Koss MJ; Choi CY
    Invest Ophthalmol Vis Sci; 2015 Jul; 56(8):4817-22. PubMed ID: 26218910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progression of pharmacologic vitreolysis research].
    Zhou H; Ye J
    Zhonghua Yan Ke Za Zhi; 2014 Mar; 50(3):225-9. PubMed ID: 24841819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microplasmin: ex vivo characterization of its activity in porcine vitreous.
    de Smet MD; Valmaggia C; Zarranz-Ventura J; Willekens B
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):814-9. PubMed ID: 18806295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posterior vitreous detachment with plasmin in the isolated human eye.
    Li X; Shi X; Fan J
    Graefes Arch Clin Exp Ophthalmol; 2002 Jan; 240(1):56-62. PubMed ID: 11954782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic vitreodynamics and molecular flux.
    Goldenberg DT; Trese MT
    Dev Ophthalmol; 2009; 44():31-36. PubMed ID: 19494650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objective of pharmacologic vitreolysis.
    Gandorfer A
    Dev Ophthalmol; 2009; 44():1-6. PubMed ID: 19494646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic degradation identifies components responsible for the structural properties of the vitreous body.
    Filas BA; Zhang Q; Okamoto RJ; Shui YB; Beebe DC
    Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):55-63. PubMed ID: 24222300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Ultrastructural Localization of Type II, IV, and VI Collagens at the Vitreoretinal Interface.
    Bu SC; Kuijer R; van der Worp RJ; Li XR; Hooymans JM; Los LI
    PLoS One; 2015; 10(7):e0134325. PubMed ID: 26230410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between vitrectomy and the morphology and function of the retina].
    Terasaki H
    Nippon Ganka Gakkai Zasshi; 2003 Dec; 107(12):836-64; discussion 865. PubMed ID: 14733133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
    Costa Ede P; Rodrigues EB; Farah ME; Sebag J; Meyer CH
    Curr Pharm Biotechnol; 2011 Mar; 12(3):410-22. PubMed ID: 20939794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.